Demographic and clinical patient characteristics according to non-inclusion/inclusion in a recent transmission cluster, 2014–16 (n=1121)
| . | Total . | Not included in a cluster . | Included in a small cluster (≤3) . | Included in a large cluster (>3) . | Pa . |
|---|---|---|---|---|---|
| n (%) | 1121 (100) | 664 (59) | 214 (19) | 243 (22) | |
| Age (years), median (IQR) | 36 (28–45) | 38 (30–47) | 34 (26–45) | 31 (26–39) | <0.001 |
| Male, n (%) | 1009 (90) | 568 (86) | 200 (93) | 241 (99) | <0.001 |
| Country of birth, n (%) | <0.001 | ||||
| France | 790 (70) | 448 (67) | 158 (74) | 184 (76) | |
| other European countries | 37 (3) | 23 (3) | 5 (2) | 9 (4) | |
| sub-Saharan Africa | 74 (7) | 66 (10) | 4 (2) | 4 (2) | |
| other/unknown | 220 (20) | 127 (19) | 47 (22) | 46 (19) | |
| CDC stage, n (%) | 0.199 | ||||
| A | 827 (96) | 495 (96) | 153 (94) | 179 (98) | |
| B | 20 (2) | 11 (2) | 5 (3) | 4 (2) | |
| C | 13 (1) | 8 (2) | 5 (3) | 0 (0) | |
| Route of transmission, n (%) | <0.001 | ||||
| MSM | 788 (70) | 421 (63) | 170 (82) | 197 (81) | |
| heterosexual | 199 (18) | 168 (25) | 19 (9) | 12 (5) | |
| IVDU | 5 (0) | 4 (1) | 1 (0) | 0 (0) | |
| other/unknown | 129 (12) | 77 (11) | 18 (9) | 31 (14) | |
| Region of diagnosis | 0.125 | ||||
| Paris area | 476 (42) | 273 (41) | 86 (40) | 117 (48) | |
| other region | 645 (58) | 391 (59) | 128 (60) | 126 (52) | |
| Year of diagnosis, n (%) | <0.001 | ||||
| 2014 | 355 (32) | 196 (30) | 93 (43) | 66 (27) | |
| 2015 | 381 (34) | 229 (34) | 60 (28) | 92 (38) | |
| 2016 | 385 (34) | 239 (36) | 61 (29) | 86 (35) | |
| Subtype | <0.001 | ||||
| B | 628 (56) | 365 (55) | 154 (72) | 109 (45) | |
| CRF02_AG | 222 (20) | 122 (18) | 30 (14) | 70 (29) | |
| URF | 64 (6) | 29 (4) | 11 (5) | 24 (10) | |
| other | 207 (18) | 148 (22) | 19 (9) | 40 (16) | |
| Viral load (log10 copies/mL), median (IQR) | 5.51 (4.71–6.46) | 5.49 (4.72–6.36) | 5.72 (4.86–6.60) | 5.51 (4.62–6.56) | 0.322 |
| CD4 cell count (cells/mm3), median (IQR) | 478 (329–636) | 460 (319–631) | 476 (329–643) | 498 (379–640) | 0.120 |
| . | Total . | Not included in a cluster . | Included in a small cluster (≤3) . | Included in a large cluster (>3) . | Pa . |
|---|---|---|---|---|---|
| n (%) | 1121 (100) | 664 (59) | 214 (19) | 243 (22) | |
| Age (years), median (IQR) | 36 (28–45) | 38 (30–47) | 34 (26–45) | 31 (26–39) | <0.001 |
| Male, n (%) | 1009 (90) | 568 (86) | 200 (93) | 241 (99) | <0.001 |
| Country of birth, n (%) | <0.001 | ||||
| France | 790 (70) | 448 (67) | 158 (74) | 184 (76) | |
| other European countries | 37 (3) | 23 (3) | 5 (2) | 9 (4) | |
| sub-Saharan Africa | 74 (7) | 66 (10) | 4 (2) | 4 (2) | |
| other/unknown | 220 (20) | 127 (19) | 47 (22) | 46 (19) | |
| CDC stage, n (%) | 0.199 | ||||
| A | 827 (96) | 495 (96) | 153 (94) | 179 (98) | |
| B | 20 (2) | 11 (2) | 5 (3) | 4 (2) | |
| C | 13 (1) | 8 (2) | 5 (3) | 0 (0) | |
| Route of transmission, n (%) | <0.001 | ||||
| MSM | 788 (70) | 421 (63) | 170 (82) | 197 (81) | |
| heterosexual | 199 (18) | 168 (25) | 19 (9) | 12 (5) | |
| IVDU | 5 (0) | 4 (1) | 1 (0) | 0 (0) | |
| other/unknown | 129 (12) | 77 (11) | 18 (9) | 31 (14) | |
| Region of diagnosis | 0.125 | ||||
| Paris area | 476 (42) | 273 (41) | 86 (40) | 117 (48) | |
| other region | 645 (58) | 391 (59) | 128 (60) | 126 (52) | |
| Year of diagnosis, n (%) | <0.001 | ||||
| 2014 | 355 (32) | 196 (30) | 93 (43) | 66 (27) | |
| 2015 | 381 (34) | 229 (34) | 60 (28) | 92 (38) | |
| 2016 | 385 (34) | 239 (36) | 61 (29) | 86 (35) | |
| Subtype | <0.001 | ||||
| B | 628 (56) | 365 (55) | 154 (72) | 109 (45) | |
| CRF02_AG | 222 (20) | 122 (18) | 30 (14) | 70 (29) | |
| URF | 64 (6) | 29 (4) | 11 (5) | 24 (10) | |
| other | 207 (18) | 148 (22) | 19 (9) | 40 (16) | |
| Viral load (log10 copies/mL), median (IQR) | 5.51 (4.71–6.46) | 5.49 (4.72–6.36) | 5.72 (4.86–6.60) | 5.51 (4.62–6.56) | 0.322 |
| CD4 cell count (cells/mm3), median (IQR) | 478 (329–636) | 460 (319–631) | 476 (329–643) | 498 (379–640) | 0.120 |
aStatistically significant P values (<0.05) are indicated in bold.
Demographic and clinical patient characteristics according to non-inclusion/inclusion in a recent transmission cluster, 2014–16 (n=1121)
| . | Total . | Not included in a cluster . | Included in a small cluster (≤3) . | Included in a large cluster (>3) . | Pa . |
|---|---|---|---|---|---|
| n (%) | 1121 (100) | 664 (59) | 214 (19) | 243 (22) | |
| Age (years), median (IQR) | 36 (28–45) | 38 (30–47) | 34 (26–45) | 31 (26–39) | <0.001 |
| Male, n (%) | 1009 (90) | 568 (86) | 200 (93) | 241 (99) | <0.001 |
| Country of birth, n (%) | <0.001 | ||||
| France | 790 (70) | 448 (67) | 158 (74) | 184 (76) | |
| other European countries | 37 (3) | 23 (3) | 5 (2) | 9 (4) | |
| sub-Saharan Africa | 74 (7) | 66 (10) | 4 (2) | 4 (2) | |
| other/unknown | 220 (20) | 127 (19) | 47 (22) | 46 (19) | |
| CDC stage, n (%) | 0.199 | ||||
| A | 827 (96) | 495 (96) | 153 (94) | 179 (98) | |
| B | 20 (2) | 11 (2) | 5 (3) | 4 (2) | |
| C | 13 (1) | 8 (2) | 5 (3) | 0 (0) | |
| Route of transmission, n (%) | <0.001 | ||||
| MSM | 788 (70) | 421 (63) | 170 (82) | 197 (81) | |
| heterosexual | 199 (18) | 168 (25) | 19 (9) | 12 (5) | |
| IVDU | 5 (0) | 4 (1) | 1 (0) | 0 (0) | |
| other/unknown | 129 (12) | 77 (11) | 18 (9) | 31 (14) | |
| Region of diagnosis | 0.125 | ||||
| Paris area | 476 (42) | 273 (41) | 86 (40) | 117 (48) | |
| other region | 645 (58) | 391 (59) | 128 (60) | 126 (52) | |
| Year of diagnosis, n (%) | <0.001 | ||||
| 2014 | 355 (32) | 196 (30) | 93 (43) | 66 (27) | |
| 2015 | 381 (34) | 229 (34) | 60 (28) | 92 (38) | |
| 2016 | 385 (34) | 239 (36) | 61 (29) | 86 (35) | |
| Subtype | <0.001 | ||||
| B | 628 (56) | 365 (55) | 154 (72) | 109 (45) | |
| CRF02_AG | 222 (20) | 122 (18) | 30 (14) | 70 (29) | |
| URF | 64 (6) | 29 (4) | 11 (5) | 24 (10) | |
| other | 207 (18) | 148 (22) | 19 (9) | 40 (16) | |
| Viral load (log10 copies/mL), median (IQR) | 5.51 (4.71–6.46) | 5.49 (4.72–6.36) | 5.72 (4.86–6.60) | 5.51 (4.62–6.56) | 0.322 |
| CD4 cell count (cells/mm3), median (IQR) | 478 (329–636) | 460 (319–631) | 476 (329–643) | 498 (379–640) | 0.120 |
| . | Total . | Not included in a cluster . | Included in a small cluster (≤3) . | Included in a large cluster (>3) . | Pa . |
|---|---|---|---|---|---|
| n (%) | 1121 (100) | 664 (59) | 214 (19) | 243 (22) | |
| Age (years), median (IQR) | 36 (28–45) | 38 (30–47) | 34 (26–45) | 31 (26–39) | <0.001 |
| Male, n (%) | 1009 (90) | 568 (86) | 200 (93) | 241 (99) | <0.001 |
| Country of birth, n (%) | <0.001 | ||||
| France | 790 (70) | 448 (67) | 158 (74) | 184 (76) | |
| other European countries | 37 (3) | 23 (3) | 5 (2) | 9 (4) | |
| sub-Saharan Africa | 74 (7) | 66 (10) | 4 (2) | 4 (2) | |
| other/unknown | 220 (20) | 127 (19) | 47 (22) | 46 (19) | |
| CDC stage, n (%) | 0.199 | ||||
| A | 827 (96) | 495 (96) | 153 (94) | 179 (98) | |
| B | 20 (2) | 11 (2) | 5 (3) | 4 (2) | |
| C | 13 (1) | 8 (2) | 5 (3) | 0 (0) | |
| Route of transmission, n (%) | <0.001 | ||||
| MSM | 788 (70) | 421 (63) | 170 (82) | 197 (81) | |
| heterosexual | 199 (18) | 168 (25) | 19 (9) | 12 (5) | |
| IVDU | 5 (0) | 4 (1) | 1 (0) | 0 (0) | |
| other/unknown | 129 (12) | 77 (11) | 18 (9) | 31 (14) | |
| Region of diagnosis | 0.125 | ||||
| Paris area | 476 (42) | 273 (41) | 86 (40) | 117 (48) | |
| other region | 645 (58) | 391 (59) | 128 (60) | 126 (52) | |
| Year of diagnosis, n (%) | <0.001 | ||||
| 2014 | 355 (32) | 196 (30) | 93 (43) | 66 (27) | |
| 2015 | 381 (34) | 229 (34) | 60 (28) | 92 (38) | |
| 2016 | 385 (34) | 239 (36) | 61 (29) | 86 (35) | |
| Subtype | <0.001 | ||||
| B | 628 (56) | 365 (55) | 154 (72) | 109 (45) | |
| CRF02_AG | 222 (20) | 122 (18) | 30 (14) | 70 (29) | |
| URF | 64 (6) | 29 (4) | 11 (5) | 24 (10) | |
| other | 207 (18) | 148 (22) | 19 (9) | 40 (16) | |
| Viral load (log10 copies/mL), median (IQR) | 5.51 (4.71–6.46) | 5.49 (4.72–6.36) | 5.72 (4.86–6.60) | 5.51 (4.62–6.56) | 0.322 |
| CD4 cell count (cells/mm3), median (IQR) | 478 (329–636) | 460 (319–631) | 476 (329–643) | 498 (379–640) | 0.120 |
aStatistically significant P values (<0.05) are indicated in bold.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
